Evolus Inc (EOLS)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
EOLS
Evolus Inc
$7.84
-0.88%
HEALTHCARE · Cap: $599.74M
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.26
+0.83%
HEALTHCARE · Cap: $58.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1459334% more annual revenue ($4.62T vs $316.49M). TAK leads profitability with a -3.5% profit margin vs -10.8%. TAK earns a higher WallStSmart Score of 53/100 (C-).
EOLS
Avoid34
out of 100
Grade: F
TAK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+71.1%
Fair Value
$14.90
Current Price
$7.84
$7.06 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 21.2% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18730.0% — below average capital efficiency
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : EOLS
The strongest argument for EOLS centers on Debt/Equity, Revenue Growth. Revenue growth of 21.2% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.43 suggests the stock is reasonably priced for its growth.
Bear Case : EOLS
The primary concerns for EOLS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
EOLS profiles as a growth stock while TAK is a turnaround play — different risk/reward profiles.
EOLS carries more volatility with a beta of 1.36 — expect wider price swings.
EOLS is growing revenue faster at 21.2% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (53/100 vs 34/100) and 10.2% revenue growth. EOLS offers better value entry with a 71.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evolus Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?